PMID: 9186685Apr 5, 1997Paper

Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86

Annals of the New York Academy of Sciences
P Lane

Abstract

In recent years, it has become clear that the fate of lymphocyte interactions with antigen is determined not only by signals through antigen-specific receptors, but by interactions between pairs of accessory molecules. One such crucial pair of ligands is that between CD80/CD86, expressed by professional APCs and activated T and B cells, and CD28 (resting and activated T cells primarily) and CTLA4 (activated T cells). Signals in this system can amplify (CD28) or inhibit (CTLA4) T cell responses. The uses of soluble competitors for CD28 (CTLA4-Ig) and agonists for the inhibitory receptor CTLA4 (CD80-Ig) offer therapeutic possibilities to tailor autoimmune responses in nonpathogenic directions.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·L A TurkaD Gordon
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D J LenschowJ A Bluestone
Aug 26, 1994·Science·B K FinckD Wofsy
Jan 1, 1995·European Journal of Immunology·M R Prabhu DasV K Kuchroo
Sep 1, 1994·Immunity·J M GreenC B Thompson
May 1, 1995·The Journal of Experimental Medicine·M H SayeghL A Turka
Jul 1, 1995·European Journal of Immunology·A D McLellanD N Hart
Apr 1, 1993·The Journal of Experimental Medicine·E A Ranheim, T J Kipps
Jun 1, 1993·The Journal of Experimental Medicine·F A Harding, J P Allison
Aug 1, 1994·Immunity·J XuR A Flavell
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·K G SmithD M Tarlinton

❮ Previous
Next ❯

Citations

Oct 2, 2001·Critical Reviews in Oncology/hematology·P M McLaughlinL F de Leij
Jan 29, 2000·Scandinavian Journal of Immunology·K J ClarkM A Shapiro
Jun 3, 1999·The New England Journal of Medicine·R S Schwartz
Nov 26, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Tom Simones, David M Shepherd
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·E Israël-AssayagY Cormier
Sep 16, 2000·American Journal of Respiratory and Critical Care Medicine·A KarnowskiM C Lamers
Oct 7, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Steffen Schlehuber, Arne Skerra
Dec 18, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marloes J M Olde NordkampLinde Meyaard
Jun 7, 2008·The Journal of Arthroplasty·Paul M Whittingham-JonesTimothy W R Briggs
Jul 29, 2015·Evaluation and Program Planning·Valentina Anzoise, Stefania Sardo
Jul 21, 2004·Journal of the Neurological Sciences·R E Gonsette
Mar 4, 2014·PloS One·Mariano Sanchez-LockhartJim Miller
Jan 29, 2005·Drug Discovery Today·Steffen Schlehuber, Arne Skerra
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Michael LimE Antonio Chiocca
Feb 1, 2000·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·I A SchrijverJ D Laman
Sep 24, 1999·Biochemical and Biophysical Research Communications·H AkariA Adachi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.